Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
EPA CPDat observed this chemical in 0 composition records across product categories including unclassified products.
Concern score
The concern value reflects this ingredient's chemical identity — its hazard profile from the published classifications and regulatory status below — not the safety of a product it appears in. A score near 40 is the baseline for ingredients with no specific signal (water scores 40 by design), so a mid-range value is not a safety verdict.
Concern score 5/100 (low) · high confidence.
Prevalence of GLYCERYL DIBEHENATE in our catalog (fda_ndc).
Products
1
Typical roles
Catalog
Context-specific fit derived from published classifications and the current ingredient evidence profile.
Fragrance avoidance
No fragrance-linked caution surfaced in the current profile.
This ingredient does not currently read as a fragrance-linked driver in the published evidence and hazard profile.
The published evidence profile currently shaping this ingredient record.
Primary documents currently linked to this ingredient record.
Structured claim signals pulled from linked ingredient research.
Published jurisdiction-level classifications and regulatory designations for this ingredient.
US
EPA
EPA CPDat observed this chemical in 0 composition records across product categories including unclassified products. EPA CPDat classifies this chemical for functional uses including UV stabilizer.
US
EPA
EPA CPDat observed this chemical in 2 composition records across product categories including Personal care.
US
FDA
Advil dual action shelf
Route: ORAL; Dosage form: CAPSULE; Maximum daily exposure: 51 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, DELAYED RELEASE; Maximum daily exposure: 31 mg
US
FDA
Route: ORAL; Dosage form: CAPSULE, EXTENDED RELEASE; Maximum daily exposure: 1 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SOLUTION; Maximum daily exposure: 8 mg
US
FDA
Route: ORAL; Dosage form: POWDER, FOR SUSPENSION; Potency: 0.08 mg
US
FDA
Route: ORAL; Dosage form: SOLUTION; Maximum daily exposure: 3 mg
US
FDA
Route: ORAL; Dosage form: TABLET; Maximum daily exposure: 120 mg
US
FDA
Route: ORAL; Dosage form: TABLET, COATED; Maximum daily exposure: 19 mg
US
FDA
Route: ORAL; Dosage form: TABLET, DELAYED RELEASE; Maximum daily exposure: 75 mg
US
FDA
Route: ORAL; Dosage form: TABLET, EXTENDED RELEASE; Maximum daily exposure: 761 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED; Maximum daily exposure: 77 mg
US
FDA
Route: ORAL; Dosage form: TABLET, FILM COATED, EXTENDED RELEASE; Maximum daily exposure: 10 mg
US
FDA
Route: ORAL; Dosage form: TABLET, ORALLY DISINTEGRATING; Maximum daily exposure: 6 mg
US
FDA
FDA NDC lists this ingredient in 1 active drug products and 1 total products.
US
FDA
openFDA substance registry classifies this ingredient as mixture.